Alector, Inc.

Equities

ALEC

US0144421072

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 03/06/2024 BST			5-day change	1st Jan Change
5.03 ^USD	+2.24%		+0.80%	-36.97%

05-14	Transcript : Alector, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:55 AM
05-08	Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024	CI

Alector, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

February 28, 2023 at 09:19 pm

Alector, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 133.31 million compared to USD 36.33 million a year ago. Basic loss per share from continuing operations was USD 1.62 compared to USD 0.45 a year ago.

Latest news about Alector, Inc.

Transcript : Alector, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:55 AM	05-14
Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024	05-08	CI
Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Certain Restricted Stock Units of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	04-16	CI
Certain Options of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	04-16	CI
Certain Common Stock of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	04-16	CI
Alector, Inc. Announces Board Changes	03-21	CI
Transcript : Alector, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM	03-13
Transcript : Alector, Inc., 2023 Earnings Call, Feb 27, 2024	02-27
Alector, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Alector, Inc. Provides Revenue Guidance for the Year Ending 2024	02-27	CI
Alector, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-27	CI
Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer?S Disease	02-08	CI
Alector, GSK Say FDA Grants Breakthrough Therapy Label For Frontotemporal Dementia Treatment	02-07	MT
GSK: breakthrough therapy status in dementia	02-07	CF
Alector, GSK Get FDA Breakthrough Designation for Latozinemab	02-07	DJ
Alector, Inc. Announces the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation to Latozinemab	02-07	CI
Alector Closes $75 Million Public Stock Offering	01-19	MT
Alector Tumbles After Pricing $75 Million Stock Offering	01-17	MT
Sector Update: Health Care Stocks Decline Pre-Bell Wednesday	01-17	MT
Alector Plans Common Stock Offering; Shares Fall After-Hours	01-16	MT
North American Morning Briefing : Volatility -2-	12-15	DJ
Alector Shares Rise After Stifel Upgrade	12-14	MT
Stifel Upgrades Alector to Buy From Hold, Adjusts Price Target to $15 From $8	12-14	MT
Transcript : Alector, Inc. - Special Call	12-13

Chart Alector, Inc.

Duration

Period

More charts

Company Profile

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimerâs disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.

Sector

Biotechnology & Medical Research

Calendar

12/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Alector, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.03 USD

Average target price

15.44 USD

Spread / Average Target

+207.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALECTOR, INC.	-36.97%	485M
VERTEX PHARMACEUTICALS INCORPORATED	+15.55%	121B
REGENERON PHARMACEUTICALS, INC.	+12.66%	107B
BIONTECH SE	-2.53%	24.82B
ARGENX SE	+1.14%	22.48B
GENMAB A/S	-9.35%	18.32B
WUXI APPTEC CO., LTD.	-42.28%	16.33B
BEIGENE, LTD.	-18.92%	15.31B
NEUROCRINE BIOSCIENCES, INC.	+6.19%	14.08B
SAREPTA THERAPEUTICS, INC.	+28.83%	11.74B

Bio Therapeutic Drugs